Is your shoulder cartilage damage suitable for this injection?

The most important question at the assessment stage is not how much pain you have, but what type of damage your shoulder scan reveals. ChondroFiller injection is indicated for focal, well-defined cartilage lesions in the glenohumeral joint — typically ICRS or Outerbridge Grade III to IV — where the damage is concentrated in a defined area rather than spread across the joint surface. The glenohumeral joint is a named indication in ChondroFiller's CE certification, alongside the knee, hip, ankle, and elbow.

The structural requirement is precise: the cartilage and subchondral bone surrounding the defect must remain intact. The collagen scaffold anchors to these healthy borders and draws progenitor cells inward from adjacent tissue; without sound margins, the scaffold has no foundation to work from. Diffuse glenohumeral osteoarthritis — where joint-surface thinning is widespread — falls outside this indication for that reason.

Diagnosing a focal chondral defect in the shoulder is not straightforward from symptoms alone. Deep aching, restricted range of motion, and pain on loading are equally consistent with rotator cuff pathology or subacromial impingement. Clinical examination cannot reliably separate these conditions, which is why an MRI scan is a mandatory step before any treatment decision. The scan establishes whether a focal lesion is actually present, confirms its size and depth, and rules out concurrent structural problems that would change the management approach entirely. A proper assessment will give a clear answer on where you stand.

How the collagen scaffold recruits the body's own repair cells

Unlike biological therapies that deliver living cells into a joint, ChondroFiller is entirely acellular — its single active component is a purified Type I collagen hydrogel containing no donor or laboratory-grown cells whatsoever. What it provides is architecture, not biology: a three-dimensional physical framework that the body's own repair processes can colonise.

Delivery uses a dual-chamber syringe that keeps the collagen components separate until the moment of injection. Once placed into the defect under ultrasound guidance, the material conforms precisely to the geometry of the lesion and transitions from liquid to stable hydrogel within approximately three to five minutes. At that point it bonds to the surrounding cartilage margins — the intact borders that the previous section described as a prerequisite — and forms the scaffold for matrix-induced chondrogenesis.

Cell recruitment is entirely autologous. Progenitor cells migrate from the surrounding tissue into the collagen matrix and proliferate there, progressively building new repair tissue within the scaffold's structure. A 2025 ex vivo osteochondral explant study (n=61) provided direct laboratory confirmation of this process, recording a 2.4-fold increase in DNA content inside ChondroFiller-treated defects by day 14 — measurable evidence of in-scaffold cell proliferation under physiologically relevant conditions.

A standard injection volume is approximately 2.3 mL. Precise, flush placement is technically important: data from a 2025 wrist series found that fibrous tissue formation occurred in overfilled defects, whereas flush applications were free of this complication. This is why the clinician's technique — including how the material is placed and how volume is judged against the defect — directly influences the quality of the tissue that forms.

What to expect on the day of the injection

The appointment itself is straightforward. ChondroFiller injection is delivered as an outpatient procedure under real-time ultrasound guidance — no general anaesthetic, no theatre booking, no surgical incision. The clinician uses live imaging to track both the needle tip and the glenohumeral joint space simultaneously, which allows the collagen scaffold to be placed precisely within the defect pocket rather than estimated from surface landmarks alone.

After the injection, a short restriction period applies. NSAIDs should be avoided — they can interfere with the scaffold's gelation and with the early inflammatory signals that support progenitor cell migration. Intense heat, saunas, and heavy sweating are similarly off-limits during this initial phase to allow the collagen matrix to set without disruption. Most patients leave the clinic the same day. An early response review is typically scheduled at approximately six weeks post-injection.

For shoulder patients, one practical point about activity is worth noting. A 2024 biomechanical in vitro study found that in the acute phase — before stable gelation is established — the scaffold offers limited protection to opposing cartilage surfaces under cyclic loading. Loaded mobilisation of the shoulder, including overhead activity, resistance training, and weighted exercise, should therefore be delayed until the gel has stabilised. This is not a reason for concern; it is simply a timing consideration, and the treating clinician will give specific guidance based on the individual defect and how the post-injection period progresses.

What the clinical evidence shows — and where it comes from

No randomised controlled trial for glenohumeral ChondroFiller injection has been published as of August 2026. The available evidence comes from other joints with comparable focal chondral defect pathology — and that extrapolation should be stated plainly rather than papered over.

The strongest clinical anchor is a 2016 randomised multicentre knee study (n=13 ChondroFiller) that recorded significant IKDC score improvements at 3, 6, and 12 months with no adverse events; MRI using MOCART scoring confirmed good defect filling at baseline and measurable cartilage maturation through to 52 weeks. A 2024 knee series (n=17) reproduced those functional gains, with statistically significant Lysholm and IKDC improvements across the same follow-up intervals.

Hip data extends the timeline. A prospective cohort (n=26) tracking acetabular cartilage defects for up to five years found that 17 of 21 patients at follow-up achieved good or excellent outcomes — but those with pre-existing osteoarthritis (Tönnis grades 2–3) fared poorly, a finding that directly reinforces the non-OA selection criterion. Good results clustered around patients with focal lesions in otherwise structurally sound joints.

A 2025 wrist series added structural evidence: treated defects scored a median Outerbridge grade 1.5 versus 3.0 in untreated controls (p=0.006). Across joint types, post-injection MRI has confirmed reduction in bone marrow oedema, diminished periarticular effusion, and measurable joint space widening alongside improvements in NRS pain scores and DASH functional scores — changes in joint architecture, not just symptom relief.

For someone weighing up the shoulder application, the honest position is this: the biological mechanism is consistent across joint types, the functional outcomes in well-selected non-OA patients are encouraging, and the evidence gap — no glenohumeral-specific RCT — is real. Results comparable to those seen in the knee and hip cohorts are plausible; they are not guaranteed, and a suitability assessment should be expected to spell out what that difference means for your particular lesion.

The honest limitations: what this treatment cannot do

Three facts about this treatment are worth having in front of you before any clinical conversation takes place.

ChondroFiller injection is not available on the NHS and does not carry FDA approval. In the UK it is accessed through self-funded private pathways only. At the London Cartilage Clinic on Harley Street, guide costs range from £3,000 for a single-box treatment to £8,000 for three boxes, inclusive of consultation, ultrasound imaging, IV antibiotic cover, and the six-week follow-up review. Private medical insurance does not routinely cover it.

That cost context is precisely why an expert eligibility assessment — including MRI review — is the correct first step, not an optional formality. The purpose of the assessment is to establish from imaging whether the anatomy of the damage genuinely falls within the treatment's indicated range. Patients whose lesions are diffuse rather than focal, or whose surrounding tissue cannot support stable scaffold integration, are identified at that stage and directed to more appropriate options. The assessment exists to protect that group as much as to confirm suitability for those who proceed.

Two further points can be stated briefly, since the sections above address them in detail. The evidence base across all joints includes no published glenohumeral RCT as of August 2026; shoulder-specific outcome certainty rests on mechanistically consistent extrapolation, not direct trial data. And the initial post-injection mobility restriction described earlier is non-negotiable — the scaffold cannot protect opposing joint surfaces under load until stable gelation is established, and disregarding that window risks the result.

Getting assessed at the London Cartilage Clinic

For patients based in London or the surrounding area, ChondroFiller injection is delivered at the London Cartilage Clinic on Harley Street — the UK's certified delivery centre for the treatment. Professor Paul Y. F. Lee leads its delivery; consistent, flush placement under real-time ultrasound guidance is technically demanding, and application quality has a material bearing on how well the scaffold integrates with the surrounding tissue.

The starting point for any patient is an assessment consultation that includes a review of current MRI imaging. Where that imaging confirms a focal glenohumeral defect sitting within the CE-certified indication — and rules out diffuse osteoarthritis or structural damage that falls outside the treatment's range — the injection can be discussed as a practical next step in the treatment plan.

Assessment appointments and further information are available at londoncartilage.com.

1. [1] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
2. [2] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
3. [3] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
5. [5] IMPLANTATION OF CHONDROFILLER LIQUID® AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS OF THE KNEE JOINT. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
6. [6] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y